TB-500 storage and stability are best when the lyophilized powder stays sealed, dry, dark and cold. Moisture governs the outcome more than freezer temperature does. Let every cold vial reach room temperature before opening, confirm from the certificate which molecule you hold, date every container, and treat undated material as unusable.
- TB-500 is a trade name covering two different molecules: full-length thymosin β4 near 4,960 Da and the Ac-LKKTETQ fragment near 889 Da.
- Moisture, not freezer temperature, is the dominant degradation driver for a dry hygroscopic peptide.
- Neither form contains cysteine, so disulfide scrambling is not a failure mode; oxidation is limited to Met6 in the full-length peptide.
- Asn26 is followed by proline, which places its deamidation among the slower cases rather than the faster ones.
- Equilibrating a sealed vial to room temperature before opening prevents the condensation uptake that is the most common avoidable handling error.
- Net peptide content, not gross vial mass, tells you how much of the vial is peptide.
What this guide covers
Think of it like a box of crackers. Sealed, they keep for a long time, but leave the bag open on a humid day and they go soft fast. Dry TB-500 powder is similar: keeping water out does more than turning the freezer colder.
This page sorts out which of two materials the TB-500 label covers, how it degrades and what slows that down, the sequence features that matter on the bench, conditions for each physical state, how to open a cold vial without letting water in, what the record should hold, the red flags, and the regulatory status. A bottom line comes last.
- Moisture — the dominant driver, delivered mostly by condensation
- Temperature — a rate modifier, not the mechanism
- Container surfaces — adsorption of the net-cationic fragment on bare glass
- Cold openings: condensation lands straight on the cake
- Light and oxygen — one methionine to lose, and only in the full-length form
What is in a TB-500 vial?
TB-500 is a supplier name. It has no pharmacopeial monograph behind it and it does not designate one defined chemical entity, which matters before any storage question can be answered sensibly. Two quite different materials circulate under the label.
The first is full-length thymosin β4: a 43-residue, N-terminally acetylated polypeptide of roughly 4,960 Da, sequence beginning Ac-SDKPDMAEIE and ending in AGES. The second is the acetylated actin-binding fragment Ac-LKKTETQ-OH, corresponding to residues 17 to 23 of that sequence, with a mass near 889 Da. A factor of five in molecular weight is not a subtlety. RP-HPLC retention, mass spectrum, solubility, net charge and adsorption behavior all differ, and so does the set of degradation routes that applies.
So the first storage control is documentary. Read the certificate of analysis for the observed mass and the stated sequence, not the trade name on the label. If the certificate reports a single deprotonated or protonated species consistent with one of those two masses, you know which molecule you are storing. If it reports only a purity percentage with no mass and no sequence, you are storing something whose identity is asserted rather than shown, and no amount of freezer discipline compensates for that.
Our documentation standard sets out which fields we expect a certificate to carry. The rest of this page assumes you have established which of the two materials is in front of you.
How does TB-500 degrade, and what controls it?
Peptides fail along a small and well-characterized set of routes. The review literature on lyophilizate instability is mature; Butreddy and colleagues surveyed the stresses and mechanisms in 2020, and that map applies here with one qualification: TB-500, in either form, is strongly hydrophilic and carries no cysteine, so two of the classic failure modes are off the table.
| Route | Driver | Site in this sequence | Control |
|---|---|---|---|
| Backbone hydrolysis | Water activity, temperature, pH extremes | Any amide bond; Asp-Pro linkages are relatively labile | Keep the solid dry and sealed against desiccant |
| Deamidation | Water, temperature, pH above about 6 | Gln23, Gln36, Gln39; Asn26 in the full-length form | Dry storage, cold |
| Oxidation | Headspace oxygen, light, trace metals | Met6 in the full-length form only | Dark storage, minimal headspace, cold |
| Surface adsorption | Container chemistry, low concentration | Net-cationic heptapeptide on bare glass | Container material fixed and recorded in the protocol |
| Disulfide scrambling | Free thiols, oxidizing conditions | None; no cysteine in the sequence | Not applicable |
Freezer temperature does not appear as a mechanism, only as a rate modifier. Cold slows every row in that table, which is why cold storage works. Water is what runs the reactions.
Which sequence features affect storage?
Three features of this chemistry change how a vial behaves on the bench.
The full-length peptide has a single methionine at position 6 and no tryptophan or cysteine. That gives it one oxidation-sensitive residue and no more, which is unusually tidy. The heptapeptide fragment has none at all. Oxidative loss is therefore a smaller concern here than it is for sequences carrying several susceptible residues, though light-protected storage still costs nothing.
Asparagine 26 in the full-length sequence is followed by proline. Deamidation proceeds through a cyclic succinimide intermediate, and the residue on the C-terminal side of the asparagine strongly governs how fast that intermediate forms. Robinson and Robinson's pentapeptide work established the ordering: glycine on that side is fast, proline is among the slowest, because the tertiary amide nitrogen cannot make the nucleophilic attack the mechanism requires. Asn-Pro is close to the best case. The glutamines are slower still. Deamidation is unlikely to be the first thing that goes wrong.
Net charge differs between the two materials and shows up in handling. Full-length thymosin β4 is strongly acidic, with many glutamate and aspartate residues and an isoelectric point in the mid-4s. The Ac-LKKTETQ fragment carries two lysines against one glutamate, so it is net cationic at neutral pH. Cationic peptides adsorb to the deprotonated silanol groups on bare glass, and that loss is real and invisible. Fix the container material in the protocol and keep it fixed across a series. Switching from polypropylene to untreated glass mid-study is a good way to generate a trend that has nothing to do with the experiment.
Both forms are hygroscopic. Highly charged lyophilizates take up atmospheric water quickly, and residual counterion from purification, usually trifluoroacetate or acetate, adds to that tendency. A cake that has gone from fluffy to glassy or shrunken has almost certainly picked up water.
What conditions suit each physical state?
| State | Temperature | Light | Relative horizon | Why |
|---|---|---|---|---|
| Sealed powder, unopened | Minus 20 °C or below, desiccated | Dark | Longest | Water excluded and every rate slowed |
| Sealed powder, working stock | 2 to 8 °C, desiccated | Dark | Shorter than frozen | Adequate where the vial is consumed inside a defined window |
| Powder in transit | Ambient | Dark, insulated | Days | A dry solid tolerates short excursions well |
The horizons are deliberately relative. ICH Q1A(R2) makes the reasoning explicit for regulated products: a shelf life is the output of a stability study run on that formulation, in that container closure, under defined conditions. Nobody has run that study on a research lot of TB-500 in your vial. A supplier who prints "stable 24 months at minus 20 °C" without a study behind it is quoting a convention. Where the certificate carries a retest date derived from real data, use it. Where it does not, the honest record says the window is unestablished and the material is judged on handling history.
How to open a cold TB-500 vial: step by step
This is the failure that does most of the damage and appears in no logbook. Take a vial from a minus 20 °C freezer into a room at 22 °C and 60 percent relative humidity. The glass is far below the dew point. Water condenses on every cold surface, including the inner wall and the cake itself the instant the stopper is lifted, and a charged lyophilizate absorbs it immediately.
Nothing about the appearance changes in a way anyone will notice. The vial goes back into the freezer with water now inside it, the ice sublimes and redeposits, and the cycle repeats on the next working day. Three months later somebody reports a purity result that does not match the certificate and the discussion turns to the supplier.
The control is dull and works:
- Let the sealed vial equilibrate to room temperature before breaking the seal, every time, with no exception for being in a hurry. Twenty to thirty minutes on the bench suits a small vial.
- Work quickly once it is open.
- Backfill with dry inert gas if your setup allows.
- Reseal against fresh desiccant.
- Note the excursion if your protocol tracks openings.
One caveat: drier is not always better in the abstract. In some lyophilized formulations a small amount of residual water stabilizes the solid by substituting for hydrogen bonds the excipient matrix cannot make. That is a formulation finding, not a storage instruction, and for an unformulated research powder the practical rule stands unchanged. Keep water out.
What should the storage record say?
Storage discipline that is not written down is not reproducible. For each vial, the minimum record is the source lot identifier, the net peptide content from the certificate, the date received, the storage location, every opening, and the initials of whoever handled it. Net peptide content is not the same as chromatographic purity: a lot at 98 percent by HPLC may be 82 percent peptide, the rest counterion and water, so the record should carry both.
The reason is practical. When a result looks wrong, the first question is whether the material was what the protocol assumed. A record that runs from sample back through vial and lot to the certificate answers that in a minute. A record that stops at "TB-500" means repeating the work, and repeating it without knowing what changed.
Two habits are worth adopting outright. Undated containers are discarded, not guessed at. And a physical observation goes in the log at every opening: cake intact, cake collapsed, closure sound. Observations recorded at the time are evidence. Observations recalled later are not. The same logic applies to any peptide held on site, and the parallel discussion in storage and stability for a lipidated peptide covers the aggregation-driven cases where the stakes are higher.
Red flags on a TB-500 vial or record
These are the signs that something has already gone wrong, or that you cannot tell:
- A certificate with only a purity percentage, no mass and no sequence. The identity is asserted rather than shown.
- "Stable 24 months at minus 20 °C" printed with no study behind it. That is a convention, not data.
- A cake that has gone from fluffy to glassy or shrunken. It has almost certainly picked up water.
- An undated container. Discard it rather than guess.
- A record that stops at "TB-500" with no lot or net peptide content.
What is the regulatory status of TB-500?
There is no FDA-approved drug product containing thymosin β4 or the Ac-LKKTETQ fragment. Formulations of thymosin β4 have been studied in clinical trials, including ophthalmic preparations, but investigational status is not approval and confers nothing on research-grade powder.
Thymosin β4 has been evaluated by FDA among bulk drug substances nominated for use in compounding and placed in the category flagged for significant safety concerns, which excludes it from lawful compounding under that pathway. The World Anti-Doping Agency prohibits TB-500 and related thymosin β4 peptides at all times under the growth factors class of its Prohibited List; that list is reissued annually and should be checked against the current edition.
Status verified August 26, 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Bottom line
Confirm from the certificate's mass and sequence whether you hold the 43-residue thymosin β4 or the Ac-LKKTETQ fragment. Keep the powder sealed, dry, dark and cold, and let every vial reach room temperature before opening, because moisture does more damage than a warmer freezer. Record net peptide content beside the lot, and discard anything undated.
Common questions
Does lyophilized TB-500 have to be kept frozen?
How do I tell whether my vial holds full-length thymosin beta-4 or the heptapeptide fragment?
Is oxidation a real concern for this peptide?
Why does net peptide content matter for storage records?
More handling guides
Sources
- Butreddy et al., International Journal of Biological Macromolecules, 2020. Review of stresses, stabilization mechanisms and analytical techniques for lyophilized protein and peptide products; supports the degradation-route table and the primacy of solid-state, low-moisture storage.
- Robinson and Robinson, deamidation rate studies in model pentapeptides (PNAS, early 2000s). Establishes the neighbouring-residue effect on asparagine deamidation rate, including the strong retarding effect of a C-terminal-side proline; supports the treatment of Asn26-Pro27 as a slow case.
- ICH Q1A(R2), Stability Testing of New Drug Substances and Products. Defines shelf life as the output of a stability study on a specified formulation and container closure; supports the position that unsupported shelf-life figures for research powders are conventions rather than measurements.
- PubChem record for thymosin β4. Source for sequence, molecular formula and monoisotopic and average mass used in the identity discussion and the mass-based distinction between the full-length peptide and the heptapeptide fragment.
